# Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML

> **NCT07490288** · NA · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 30 (estimated)

## Conditions studied

- AML

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Azacitidine
- **DRUG:** Liposomal Mitoxantrone
- **DRUG:** Cytarabine
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

## Key facts

- **NCT ID:** NCT07490288
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2026-07-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07490288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07490288, "Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07490288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*